Development of personal drug and dietary treatment strategies to ameliorate cholesterol lipotoxicity and to prevent sustained HIF-1α activation in NASH and NAFLD patients should be considered. This evidence concerns the gene HIF1A and metabolic dysfunction-associated steatotic liver disease.